NewCo News: Mimetogen Launches Phase II Trial of Topical NGF in Dry Eye
By Vicki Brower
Wednesday, January 19, 2011
Focusing on ophthalmic diseases with its portfolio of small-molecule nerve growth factor (NGF) mimetic compounds, Mimetogen Pharmaceuticals Inc. is capitalizing on a large, relatively underserved medical market that is growing at about twice the rate of the general pharmaceutical sector: ophthalmology.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.